Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, Yesterday
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.

Smoking cessation after MI reduces risk of cancer

08 Sep 2017

Smoking cessation may help lower the risk of cancer, according to a recent study involving young survivors of first myocardial infarction (MI) followed-up longitudinally. Moreover, reducing cigarette smoking may be beneficial.

To assess long-term incidence of cancer after MI among current, former and never smokers, researchers followed consecutive patients aged ≤65 years discharged from eight hospitals in central Israel after MI in 1992 to 1993 for cancer and death.

They collected extensive data, including smoking habits, at the index hospitalization and four time points during follow-up. Survival methods were used to evaluated the hazard ratios (HRs) for cancer associated with smoking categories.

Of the 1,486 cancer-free participants (mean age 54 years; 81 percent men), 787 were current smokers at baseline (average daily cigarette consumption, 29). Smokers were younger than nonsmokers, more likely to be male and of lower socioeconomic status.

A total of 273 patients (18.4 percent) developed cancer over a median 21.4 years of follow-up. An association existed between baseline smoking and an approximately 40-percent excess adjusted risk of cancer. After accounting for death as a competing event, baseline smoking correlated with about 25-percent excess risk of cancer.

When changes in smoking were considered during follow-up, the excess risk was found to be limited to persistent smokers (adjusted HR, 1.75; 95 percent CI, 1.22 to 2.50). On the other hand, post- (HR, 1.14; 0.80 to 1.62) and pre-MI quitters (HR, 1.02; 0.71 to 1.47) were comparable with never smokers.

In relation to pre-MI consumption, each reduction of 10 cigarettes among persistent smokers correlated with about 10-percent lower adjust risk of cancer.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, Yesterday
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.